Completed
Bioavailability, Biopotency and Food effect study of SCD0503 compared to subcutaneous regular human insulin
2024-519502-12-00· Phase 1· Samchundang Pharm. Co. Ltd.· Source
Completed
A phase 1 glucose clamp trial investigating the bioequivalence of CVC-001 cartridge vs U.S.-Licensed Lantus® in healthy male volunteers
2024-516472-15-00· Phase 1· Civica Inc.· Source
Completed
A Research Study of a New Medicine NNC0363-1063 in Participants With Type 1 Diabetes
NCT07305805· Phase 1· Novo Nordisk A/S· Source
Completed
A Trial to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Insulin GZR33 Compared with Insulin Degludec at steady state in participants with Type 1 Diabetes
2025-523052-32-00· Phase 1· Gan & Lee Pharmaceuticals USA Corp.· Source
Completed
A Trial to Evaluate Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Insulin GZR4 Compared with Insulin Degludec and Insulin Icodec in Participants with Type 2 Diabetes
2025-522662-67-00· Phase 1· Gan & Lee Pharmaceuticals USA Corp.· Source
Completed
A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 2 Diabetes When Given by an Insulin Pump
NCT07068295· Phase 1· Novo Nordisk A/S· Source
Active, not recruiting
A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes
NCT07087795· Phase 1· Novo Nordisk A/S· Source
Completed
A Phase I Randomized, Single-center, Double-blind, Two-period Crossover Trial to Evaluate Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Insulin GZR4 Compared with Insulin Icodec in Participants with Type 2 Diabetes.
2024-519646-73-00· Phase 1· Gan & Lee Pharmaceuticals USA Corp.· Source
Completed
Phase 1 study assessing the pharmacokinetics of NEX-22A in subjects with T2D
2023-508054-25-01· Phase 1· Nanexa AB· Source
Completed
A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 1 Diabetes When Given by an Insulin Pump
NCT06809621· Phase 1· Novo Nordisk A/S· Source
Completed
A Research Study of a New Medicine NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes
NCT06685185· Phase 1· Novo Nordisk A/S· Source
Completed
CK-0045 proof-of-concept study
2024-514191-41-00· Phase 2· Cytoki Pharma ApS· Source
Completed
A Phase 2 Parallel Group Study in Adults with Type 2 Diabetes to evaluate Efficacy and Safety of GL0034
2024-513279-41-00· Phase 2· Sun Pharmaceutical Industries Limited· Source
Completed
A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)
NCT06280703· Phase 1· Eli Lilly and Company· Source
Completed
Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes
NCT06403761· Phase 1· Novo Nordisk A/S· Source
Completed
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)
NCT06309992· Phase 3· Boehringer Ingelheim· Source
Completed
A research study of a new medicine (NNC0650-0013) in healthy men
2023-506134-79-00· Phase 1· Novo Nordisk A/S· Source
Completed
A Multiple Dose Study of LY3209590 in Participants With Type 2 Diabetes
NCT06169982· Phase 1· Eli Lilly and Company· Source
Completed
Investigation of safety, tolerability and pharmacokinetics of multiple doses of NNC0113‑6856 in healthy participants, including a subset of healthy Japanese participants
2023-503891-26-00· Phase 1· Novo Nordisk A/S· Source
Active, not recruiting
A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight
NCT06151964· Phase 1/2· AstraZeneca· Source
Completed
A Translational Phase 1B, 2-Part Study to Evaluate Pharmacokinetics, Safety and Pharmacodynamics of Treatment with ATX-304 Na Salt Tablets.
2023-505967-36-00· Phase 1· Betagenon AB· Source
Completed
A research study comparing the effect of different dosing conditions on blood levels of semaglutide in a new tablet composition in healthy participants
2023-503949-65-00· Phase 1· Novo Nordisk A/S· Source
Completed
Bioequivalence study of a proposed biosimilar insulin glargine U300 with Toujeo®
2023-504509-36-00· Phase 1· Biocon Sdn. Bhd.· Source